This correlates with a significant survival benefit in glioblastoma patients with MGMT promoter methylation who receive CRT.2, 8, 9, 10 Silencing MGMT is thus a promising therapeutic target in glioblastoma and other solid tumors such as lung, breast and renal cell carcinoma where this enzyme is known to have a role in chemoresistance.11, 12, 13. This evidence concerns the gene MGMT and renal cell carcinoma.